In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
In other words, the price has increased by $0.00 from its previous closing price. On the day, 2.08 million shares were traded.
Ratios:
For a deeper understanding of Xeris Biopharma Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.67.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.Craig Hallum initiated its Buy rating on August 28, 2023, with a $4.50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 20 ’25 when Hecht Beth sold 40,000 shares for $5.43 per share. The transaction valued at 217,244 led to the insider holds 1,353,510 shares of the business.
Hecht Beth bought 40,000 shares of XERS for $205,600 on Mar 20 ’25. On Aug 12 ’24, another insider, Schmid John P., who serves as the Director of the company, bought 4,515 shares for $2.25 each. As a result, the insider paid 10,147 and bolstered with 25,200 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.15.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $6.07, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is -4.87%, while the 200-Day Moving Average is calculated to be 25.76%.
Shares Statistics:
A total of 149.43M shares are outstanding, with a floating share count of 141.94M. Insiders hold about 7.80% of the company’s shares, while institutions hold 42.83% stake in the company.
